Actively Recruiting
The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight
Led by Medical University of Warsaw · Updated on 2025-12-08
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to comprehensively assess the early and long-term effects of GLP-1 and GIP/GLP-1 analogue medications on metabolic and behavioral parameters, with particular emphasis on qualitative and quantitative dietary changes in patients undergoing treatment for overweight and obesity. Participation in the study will involve four follow-up visits per year at the Clinic of Diabetology and Internal Medicine, Central Clinical Hospital, University Clinical Clinical Hospital, Medical University of Warsaw: before treatment initiation and after 3, 6, and 12 months. The analysis will focus not only on metabolic effects (weight loss, changes in body composition, and improved biochemical parameters), but also on nutritional and behavioral aspects, including diet, appetite regulation, risk of malnutrition and muscle loss, and the occurrence of adverse events. The study will allow for a multifaceted assessment of the impact of treatment with GLP-1 and GIP/GLP-1 analogues on patients with excess body weight.
CONDITIONS
Official Title
The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-65 years
- Diagnosed obesity (BMI 630 kg/m�B2) or overweight (BMI 627 kg/m�B2) with comorbidities related to excess body weight such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
- Eligible for treatment with GLP-1 or GIP/GLP-1 analogues
- No use of GLP-1 or GIP/GLP-1 analogue medications in the year before enrollment
- Able to provide informed consent and agree to participate in the study
You will not qualify if you...
- Age under 18 or over 65 years
- Not eligible for treatment with GLP-1 or GIP/GLP-1 analogues
- Pregnant or breastfeeding
- Diagnosed eating disorders
- Active cancer or gastrointestinal conditions affecting absorption or tolerance of treatment, such as inflammatory bowel disease, extensive gastrointestinal resections, or previous bariatric surgery
- Unable to attend regular follow-up visits
- Unable or unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Klinika Diabetologii i Chorób Wewnętrznych Uniwersyteckiego Centrum Klinicznego Warszawskiego Uniwersytetu Medycznego
Warsaw, Warszawa, Poland, 02-097
Actively Recruiting
Research Team
L
Leszek Czupryniak, professor
CONTACT
M
Maja Sosnowska, master
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here